Please login to the form below

Not currently logged in
Email:
Password:

CHMP backs MSD’s CMV infection treatment

Prevymis is set to be available as an injectable and tablets

MSDMerck Sharp & Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last week.

Prevymis is one of a new class of non-nucleoside inhibitors and aims to prevent cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT).

Dr Mike England, UK Medical Director, MSD, said: “For patients undergoing an allogeneic haematopoietic stem cell transplant, complications arising from cytomegalovirus infection can be life threatening.”

Once approved, the treatment - which was acquired from German biotech AiCuris - will be available as an injectable and as film-coated tablets at 240mg and 480mg.

CMV is a common virus that can infect people of all ages and many of the infected are CMV seropositive, meaning they have CMV antibodies in their blood, which indicates a previous exposure to or primary infection with CMV.

People with a weakened immune system may give the virus a chance to reactivate, potentially leading to symptomatic disease or a secondary infection due to other pathogens, which can lead to end-organ damage.

In 2014, there were 1,346 non-paediatric allogeneic HSCT procedure performed in the UK and up to 50% of CMV seropositive recipients of allogeneic HSCT experienced CMV reactivation.

Dr England added: “We are pleased with the CHMP’s positive opinion recommending the marketing authorisation of letermovir in the European Union, which marks a significant step forward in the regulatory process as we hope to bring this product to patients in the United Kingdom.”

The US Food and Drug Administration approved letermovir once-daily tablets for oral use and injection for intravenous infusion earlier this month.

Article by
Gemma Jones

20th November 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics